GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Family Office of America Inc (OTCPK:FOFA) » Definitions » EV-to-EBIT

FOFA (Family Office of America) EV-to-EBIT : -166.91 (As of May. 18, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Family Office of America EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Family Office of America's Enterprise Value is $15.86 Mil. Family Office of America's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.10 Mil. Therefore, Family Office of America's EV-to-EBIT for today is -166.91.

The historical rank and industry rank for Family Office of America's EV-to-EBIT or its related term are showing as below:

FOFA' s EV-to-EBIT Range Over the Past 10 Years
Min: -166.91   Med: 0   Max: 0
Current: -166.91

FOFA's EV-to-EBIT is ranked worse than
100% of 457 companies
in the Medical Devices & Instruments industry
Industry Median: 19.59 vs FOFA: -166.91

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Family Office of America's Enterprise Value for the quarter that ended in Dec. 2024 was $5.45 Mil. Family Office of America's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.10 Mil. Family Office of America's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -1.74%.


Family Office of America EV-to-EBIT Historical Data

The historical data trend for Family Office of America's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Family Office of America EV-to-EBIT Chart

Family Office of America Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.99 -5.89 -11.90 -12.57 -57.34

Family Office of America Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.57 -39.60 13.09 3.91 -57.34

Competitive Comparison of Family Office of America's EV-to-EBIT

For the Medical Devices subindustry, Family Office of America's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Family Office of America's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Family Office of America's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Family Office of America's EV-to-EBIT falls into.


;
;

Family Office of America EV-to-EBIT Calculation

Family Office of America's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15.856/-0.095
=-166.91

Family Office of America's current Enterprise Value is $15.86 Mil.
Family Office of America's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Family Office of America  (OTCPK:FOFA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Family Office of America's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-0.095/5.447348
=-1.74 %

Family Office of America's Enterprise Value for the quarter that ended in Dec. 2024 was $5.45 Mil.
Family Office of America's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Family Office of America EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Family Office of America's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Family Office of America Business Description

Traded in Other Exchanges
N/A
Address
6898 S. University Boulevard, Suite 100, Centennial, CO, USA, 80122
Family Office of America Inc is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality-agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751